Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C33H38N3O14P.Gd.3H |
Molecular Weight | 891.91 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[H+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3)N(CC([O-])=O)CC([O-])=O
InChI
InChIKey=ZSDLYSDDELEVDD-UFTMZEDQSA-K
InChI=1S/C33H44N3O14P.Gd/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);/q;+3/p-3/t26-;/m1./s1
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C33H38N3O14P |
Molecular Weight | 731.6403 |
Charge | -6 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7960618http://www.prnewswire.com/news-releases/fda-approves-dotarem-gadoterate-meglumine-first-macrocyclic-and-ionic-gadolinium-based-contrast-agent-in-usa-199354771.html
Curator's Comment: # Schering AG (now subsidiary of Bayer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/31179770 |
105.0 mM [Ki] | ||
Target ID: P52209 Gene ID: 5226.0 Gene Symbol: PGD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20235752 |
73.0 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DOTAREM Approved UseIndicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Launch Date1.36373758E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. | 1994 Sep |
|
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. | 1997 May |
|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. | 2005 Apr 20 |
|
Renal safety of gadolinium-based contrast agent for ionizing radiation imaging. | 2006 Jul |
|
Gadolinium-based contrast agents and nephrotoxicity. | 2006 Nov |
|
Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data. | 2007 Aug |
|
Gadolinium contrast may be risky in kidney disease. | 2007 Jun 30 |
|
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. | 2008 Apr |
|
Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. | 2008 Aug |
|
Renal failure and gadolinium. The number of documented cases is rising. | 2008 Oct |
|
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture. | 2010 Mar |
|
Heavy metal cations permeate the TRPV6 epithelial cation channel. | 2011 Jan |
|
Toxicological safety evaluation of gadobutrol. | 2012 Nov |
|
Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. | 2013 Apr |
|
Tumor Detection at 3 Tesla with an Activatable Cell Penetrating Peptide Dendrimer (ACPPD-Gd), a T1 Magnetic Resonance (MR) Molecular Imaging Agent. | 2015 |
|
Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats. | 2015 Dec |
|
The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study). | 2015 Sep |
|
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. | 2016 Mar |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:06:44 UTC 2023
by
admin
on
Fri Dec 15 16:06:44 UTC 2023
|
Record UNII |
E65RW73PHS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C62358
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
||
|
WHO-VATC |
QV08CA11
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
||
|
WHO-ATC |
V08CA11
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
||
|
NDF-RT |
N0000175862
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
||
|
NDF-RT |
N0000180184
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
E65RW73PHS
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
m5625
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | Merck Index | ||
|
C109932
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
C81056
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
E65RW73PHS
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
73415770
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
DTXSID401027790
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
8023
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
1364290
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000089364
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
3258
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
CHEMBL1908843
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
SUB25385
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
m5881
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | Merck Index | ||
|
201688-00-8
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
87753
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY | |||
|
Gadofosveset
Created by
admin on Fri Dec 15 16:06:44 UTC 2023 , Edited by admin on Fri Dec 15 16:06:44 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
|
||
|
TARGET->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|